You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
梅花生物(600873.SH):擬轉讓山西廣生醫藥包裝50.13417%的股份予安宏資本SPV
格隆匯 08-09 18:43

格隆匯8月9日丨梅花生物(600873.SH)公佈,為專注主營業務發展,公司擬將全資子公司拉薩梅花持有的山西廣生醫藥包裝股份有限公司50.13417%股份轉讓給安宏資本 SPV轉讓完成後,拉薩梅花再是廣生醫藥的股東,公司財務報表的合併範圍將發生變化。

基於目標公司及其全資子公司山西廣生膠囊有限公司(“廣生膠囊”)無負債和無現金的假設,目標公司 100%股份的價值為人民幣12億元。拉薩梅花持有的廣生醫藥股權價值為6億元左右,轉讓完成後,拉薩梅花不再是廣生醫藥的股東,公司財務報表的合併範圍將發生變化。

根據安宏資本提供的資料顯示,安宏資本成立於1984年,是全球規模最大且最富經驗的私募股權投資基金之一。自成立以來,安宏資本在42個國家完成了超375項私募股權投資截至2021331日,安宏資本資產管理規模達750美元其在全球四大洲11個國家設立了14個辦公室,並擁有一支超過245名私募股權投資專業人士的全球團隊,遍佈北美、歐洲、拉丁美洲和亞洲主要專注於五個核心投資領域商業和金融服務業,醫療健康,工業,零售、消費品與休閒,以及科技、媒體和電信業。安宏資本35年以來致力於推動國際投資市場的發展,一直與被投資公司的管理團隊積極合作,推動被投資公司收入和利潤的可持續增長。

公司是一家專注於利用生物發酵技術進行生產、研發、銷售氨基酸類產品的生物科技公司,廣生醫藥主營業務為空心膠囊的生產、銷售。為集中優勢資源,夯實主業基礎,強化龍頭地位,發展專業化、精細化、全產業鏈的氨基酸製造平台,提高公司核心競爭力公司全資子公司拉薩梅花擬將持有的廣生醫藥 50.13417%股份整體轉讓給安宏資本,在收回投資成本實現投資收益同時實現雙贏。

拉薩梅花對外轉讓廣生醫藥股份,可能會導致公司投資收益增加,對2021度利潤產生正向影響,最終數據以公司年度經審計的財務報吿為準廣生醫藥2020資產總額為55111.2萬元,佔公司總資產的2.90%2020實現營業收入39387.86萬元,佔公司整體營業收入的2.31%廣生醫藥總體業務規模在公司佔比較小,本次交易不會對公司現有主營業務造成重大影響,不存在損害公司及公司股東利益的情形。

廣生醫藥股份轉讓完成後,拉薩梅花不再是廣生醫藥的股東,公司財務報表的合併範圍將發生變化。截止本公吿披露日,公司未對廣生醫藥提供擔保,廣生醫藥不存在佔用上市公司資金的情形。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account